Who is sponsoring NCT06955533?

NCT06955533 is sponsored by Ain Shams University.

What condition does NCT06955533 study?

NCT06955533 studies Stent Related Symptoms.

What drugs are being tested in NCT06955533?

Interventions: Double dose tamsulosin and solifenacin, Single dose tamsulosin and solifenacin.

What is the status of NCT06955533?

NCT06955533 is currently COMPLETED.

Last reviewed 2025-05-02 · How we verify

Single Dose Versus Double Dose Tamsulosin 0.4 and Solifenacin 5 in Management of Stent Related Symptoms

NCT06955533 NA COMPLETED

This study was a randomized clinical trial conducted on 64 Egyptian patients from the outpatient clinic at Ain Shams University Hospital over a six-month period from 3/2024 to 9/2024.The study population was randomized into 2 groups. Group A included 32 patients with stent related symptoms receiving double doses of tamsulosin (Tamsulin® 0.4 mg 2 capsules taken together per day) and Solifenacin 10mg (Sofenacin® 10mg tab taken once daily).Group B included 32 patients with stent related symptoms receiving a standard dose of tamsulosin (0.4 mg once daily) and solifenacin (5 mg once daily).

Details

Lead sponsor	Ain Shams University
Phase	NA
Status	COMPLETED
Enrolment	64
Start date	Mon Apr 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Aug 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Stent Related Symptoms

Interventions

Double dose tamsulosin and solifenacin
Single dose tamsulosin and solifenacin

Countries

Egypt